Skip to content

Clinical Utility of the Spyglass System in Primary Sclerosing Cholangitis (PSC)

Prospective Evaluation of the Clinical Utility of Peroral Cholangiopancreatoscopy With the Spyglass System in Patients With Sclerosing Cholangitis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01556555
Enrollment
46
Registered
2012-03-16
Start date
2008-09-30
Completion date
2011-10-31
Last updated
2021-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sclerosing Cholangitis

Keywords

Sclerosing cholangitis, Spyglass, Endoscopic retrograde cholangiopancreaticography

Brief summary

This study aim to prospectively evaluate the clinical utility of Spyglass in sclerosing cholangitis patients undergoing endoscopic retrograde cholangiopancreaticography (ERCP). Fifty patients with a definite diagnosis of sclerosing cholangitis and a clinical indication for ERCP from September 2008 and onwards will be investigated with peroral cholangioscopy using Spyglass direct visualization system. Clinical data on all patients will be collected at time of the ERCP including information on the Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD), serum liver function tests and indication for ERCP. A structured data collection form including information on Majoie Score, macroscopic features of the bile ducts at cholangioscopy, quality of the investigation, technical difficulties, and an overall judgment of whether any abnormalities observed were benign or malignant was completed by the endoscopist in conjunction with the procedure.

Interventions

None listed

Sponsors

Karolinska University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* sclerosing cholangitis with indication for ERCP * Over 18 year * informed consent

Exclusion criteria

* Not able to sign informed consent

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026